Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytostatic anticancer drug development.

Shea N Gardner1, Michael Fernandes

  • 1Biology and Biotechnology Research Program, Lawrence Livermore National Laboratory, California, USA.

Journal of Experimental Therapeutics & Oncology
|July 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Migrastatics: Redirecting R&D in Solid Cancer Towards Metastasis?

Trends in cancer·2019
Same author

Solid cancer: the new tumour spread endpoint opens novel opportunities.

British journal of cancer·2019
Same author

Letter by Olde Rikkert and Fernandes Regarding Article, "Potential Cardiovascular Disease Events Prevented With Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline".

Circulation·2019
Same author

The new US and European guidelines in hypertension: A multi-dimensional analysis.

Contemporary clinical trials·2019
Same author

Cancer, checkpoint inhibitors, and confusion.

The Lancet. Oncology·2017
Same author

Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.

Trends in cancer·2017
Same journal

Glandular odontogenic cyst: a case report in an asymptomatic patient.

Journal of experimental therapeutics & oncology·2019
Same journal

Cervical carcinosarcoma presented in advanced stage after high grade cervical displasia.

Journal of experimental therapeutics & oncology·2019
Same journal

Clear cell variant of Oral Squamous cell carcinoma.

Journal of experimental therapeutics & oncology·2019
Same journal

Giant Cervicodorsal Schwannoma.

Journal of experimental therapeutics & oncology·2019
Same journal

Effectiveness of structured teaching programme on knowledge and practice regarding care of children with leukemia among mothers.

Journal of experimental therapeutics & oncology·2019
Same journal

Clinico-pathological presentation of breast carcinoma and its correlation with β hCG.

Journal of experimental therapeutics & oncology·2019
See all related articles

Clinical trials for mechanism-based anticancer drugs need improvement. A shift to a mechanism-based framework for clinical trials and drug approval is essential for translating the potential of cytostatic drugs.

Area of Science:

  • Oncology
  • Translational Medicine
  • Drug Development

Background:

  • Vibrant scientific advancements in oncology contrast with the persistent failure of mechanism-based anticancer drugs.
  • Current clinical trial designs and drug approval processes may not adequately capture the complexities of cancer biology.

Purpose of the Study:

  • To analyze the reasons for the discrepancy between scientific progress and the clinical success of mechanism-based anticancer drugs.
  • To propose a revised framework for clinical trials and drug approval processes.

Main Methods:

  • Review of existing clinical trial methodologies for mechanism-based anticancer drugs.
  • Analysis of the current drug approval process in oncology.
  • Exploration of advanced diagnostic and predictive tools like cDNA arrays and computational models.

Related Experiment Videos

Main Results:

  • Histologic identity is insufficient for predicting tumor behavior or guiding therapy.
  • Mechanistic similarities across cancers may be more important than organ or histology for treatment prediction.
  • Tailored therapy requires rational combination treatments, dynamic disease models, and resistance-mitigation strategies.

Conclusions:

  • Clinical trials and the approval process require a shift towards a mechanism-based framework.
  • This shift is crucial for realizing the full potential of cytostatic drugs and improving cancer treatment outcomes.